1-3 of 3
Willis Navarro, MD
Close
Sort by
Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5326.
https://doi.org/10.1182/blood-2019-129277
Published: 2019
Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4071.
https://doi.org/10.1182/blood-2019-124904
Published: 2019
Journal Articles

Voriconazole Is Safe and Effective as Prophylactic Antifungal Therapy Following Allogeneic Transplantation.

Thomas Martin, MD, Meaghan Working, Ryan O’Malley, Joe Guglielmo, Neal Fischbach, MD, Lloyd Damon, MD, Willis Navarro, MD, Lawry Kaplan, MD, Richard Jacobs, John Andrews, Charles Linker, MD
Journal: Blood
Blood (2004) 104 (11): 5094.
https://doi.org/10.1182/blood.V104.11.5094.5094
Published: 2004